July 27, 2022
Authored and Edited by Yinan Liu, Ph.D.; Kara A. Specht
In CareDx, Inc. v. Natera, Inc., No. 2022-1027 (Fed. Cir. July 18, 2022), the Federal Circuit Court of Appeals affirmed that CareDx’s three patents were invalid for claiming patent-ineligible subject matter.
In 2019, CareDx sued Natera and Eurofin in the District Court for the District of Delaware for infringing its three patents entitled “Non-Invasive Diagnosis of Graft Rejection in Organ Transplant Patients.” The district court granted summary judgment finding the patents invalid as directed to patent-ineligible subject matter. The Federal Circuit affirmed.
First, under Alice Step one, the Federal Circuit found that the asserted claims are directed to natural phenomena. The claims recite collecting a bodily sample, analyzing the cfDNA, identifying naturally occurring DNA from the donor organ, and then using the natural correlation between heightened cfDNA levels and transplant health to identify a potential rejection, none of which the Court found to be inventive in this particular case. CareDx also conceded that it did not invent or discover the relationship between the donor cfDNA and the likelihood of organ transplant rejection. Second, under Alice step two, the Federal Circuit found that the asserted claims add nothing inventive because they merely recite well-known techniques in a logical combination. The specification also admitted that each step in the purported invention requires only conventional and commercially available technology.
Copyright © 2022 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Hybrid Conference
2024 California Intellectual Property Law Institute
October 21-22,2024
San Francisco
Conference
2024 Licensing Executives Society USA – Canada Annual Meeting
October 20-23, 2024
New Orleans
Conference
4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
October 8-24, 2024
Virtual
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.